clinical trial · NCT05607446
To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase1·terminated·n = 12
Allergic RhinitisTQC3564 tabletsPlacebo tabletsTQC3564 tablets, montelukast sodium tabletsPlacebo tablets, montelukast sodium tablets
brief summary
A clinical study to evaluate the efficacy and safety of tqc3564 tablets in the treatment of persistent allergic rhinitis. A total of 24 patients will be enrolled.
started
Sep 14, 2022
primary completion
May 9, 2023
completion
Dec 14, 2023
last updated
Nov 26, 2024
official title
A Single-center, Randomized, Double-blind, Two-cycle, Two-way Crossover Phase Ib Study to Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol